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was higher for open procedures (90 [4.85%] open versus 743 [0.67%] laparoscopic; 
p< 0.001). Independent risk factors for SSI included acute cholecystitis (odds ratio 
[OR], 1.53; 95% confidence interval [CI], 1.32–1.77), choledocholithiasis (OR, 1.44; 
95% CI, 1.10–1.88), open approach (OR, 5.51; 95% CI, 4.00–7.61) laparoscopic con-
verted to open approach (OR, 5.48; 95% CI, 3.99–7.54), and concurrent bile duct 
repair (OR, 4.76; 95% CI, 1.93–11.70). Females had significantly decreased risk of SSI 
(OR, 0.75; 95% CI, 0.65–0.88). ConClusions: Acute cholecystitis, choledocholithi-
asis, and concurrent bile duct repair were associated with increased risk of SSI 
after cholecystectomy, controlling for open surgery, age, and gender. Our findings 
suggest that stratification of SSI rates by these operative factors is important when 
comparing rates between facilities.
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objeCtives: Describe the prevalence of contraindications to chronic hepatitis C 
(CHC) treatment among CHC patients not receiving CHC treatment (direct-acting 
antiviral [DAA] protease inhibitors, peg-interferon alpha, or ribavirin). Methods: 
Adult patients with ≥ 2 CHC diagnoses (ICD-9-CM codes 070.44, 070.54, 070.70, 
070.71) and no DAA fills at any time in their claims history were selected from a 
de-identified US-based claims database (2010-2012); the first CHC diagnosis after 
5/13/2011 was defined as the index date. Patients with CHC treatment 6-months 
before or 12 months after the index date were excluded. All patients were required 
to have continuous eligibility and no claims for hepatitis B during the 6-months 
before (baseline) and 12-months after their index dates. Contraindications (based 
on a World Health Organization hepatitis C guide) during the baseline period were 
identified based on ICD-9 codes and described for the overall cohort as well as 
stratified by age (18-39; 40-49; 50-59; 60-69; 70-79; 80+). Results: There were 12,726 
untreated patients identified, of which 7,644 (60.1%) had ≥ 1 baseline contraindica-
tion to peg-interferon or ribavirin. Untreated patients were 56 years old on average 
and more often male (61%). Approximately 86.8% of the untreated cohort had no 
claim for any CHC treatment any time in their claims history. The most common 
contraindications included arterial hypertension (32.1%), hepatic decompensation 
(22.3%), major system impairment (19.2%), and psychiatric depression (11.0%). Age-
stratified results showed increasing prevalence of contraindications with age; rates 
of contraindications increased from 44.2% among patients 18-39 to 76.65% among 
patients 80 years old and older. ConClusions: A high proportion of untreated CHC 
patients had diagnoses for contraindicated conditions, and the prevalence of these 
contraindications increased with age.
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objeCtives: Acute pancreatitis (AP) is associated with significant morbidity and 
mortality, representing a severe economic burden for health care system. Numerous 
attempts were made to find medications able to inhibit secretion of pancreatic 
enzymes and/or inflammatory cytokines in patients with AP to prevent further 
destruction of pancreas. There exist some evidences demonstrating that a cyclooxy-
genase inhibitor lornoxicam may inhibit secretion of inflammatory cytokines. The 
objective of the study was to investigate if lornoxicam administration might be clini-
cally and economically beneficial in patients with AP. Methods: Patients with AP 
were admitted in a Moscow hospital in 2010-2011. All of them were treated according 
to existing Russian standards of AP treatment. Part of patients were administered 
with lornoxicam iv bid during the first 5 days of hospitalization (16-32 mg a day). 
The information on the patients was collected using electronic health records (EHR) 
and then analyzed. Due to differences in baseline characteristics of the groups 
of patients treated and non-treated with lornoxicam, propensity scores matching 
technique was used. Logistic regression model was built to calculate propensity to 
be treated with lornoxicam for each patient. Then mortality rates were compared for 
the matched cohorts treated and non-treated with lornoxicam. Finally, the cost of 
one prevented death was calculated. Results: Totally 264 patients were identified 
in EHR, lornoxicame was administered to 74 patients. Propensity scores adjusted 
mortality rate was 6.0% for lornoxicam group and 20.0% for control group (p= 0.037). 
Thus, administration of lornoxicam might prevent mortality in 14% patients with AP. 
The cost of the 5-day course of lornoxicam was 2,602 RUB (78 USD). Therefore, the 
cost of one prevented death due to AP was 18,586 RUB (556 USD). ConClusions: 
It was demonstrated that intravenous injections of lornoxicam in patients with AP 
was not only potentially life-saving, but also cost effective, given the low cost of 
one prevented death.
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objeCtives: To determine the Prevalence and risk factors of Hepatitis B & C 
among the Barbers and their regular shaving clients in the Hyderabad Barber 
Shops of Pakistan. Methods: A cross sectional study was conducted to deter-
mine the sero-prevalence of Hepatitis-B virus (HBV) and Hepatitis-C virus (HCV) 
among barbers and their clients in Hyderabad Sindh Pakistan and to assess their 
knowledge, attitude and practices regarding these two viruses and their mode of 
transmission. Sampling was done by using a-2-stage sampling techniques. A close 
Collaboration between stakeholders underpinned by dynamic information exchange 
is the prerequisite of a systems-based market. If other industry sectors such as 
consumer goods, finance and telecommunications serve as a model for systems-
thinking, we will expect novel linkages between health care stakeholders to become 
more prevalent as population health goals unifies incentives. While many acknowl-
edge the need to move toward a more integrated “systems thinking” approach – one 
that maps influence patterns, amplifies interdependencies, and drives collective 
outcomes, they struggle with actual implementation. A recent survey of close to 
300 Biopharma executives, EU and US Payers, and US providers reveals insight 
into their needs, their disparate perceptions, and their levels of confidence in the 
ability to shift to a systems-thinking collaborative culture. Approximately 25% of 
respondents stated they were not aligned with other stakeholders, though agree 
they need better alignment and foresee closer collaboration in the future. More 
than 70% of stakeholders believe data transparency and information-sharing is 
critically important to a successful and interoperable health care system, yet very 
few from each group were willing to demonstrate such transparency. Most health 
care industry stakeholders are ill prepared for the necessary trust-building activi-
ties required by this anticipated transition. A viable and sustainable information 
network provides the structure, aligned incentives and competitive collaboration the 
bricks and mortar, and trust the cornerstone. Until they can build that and foster a 
culture of transparency, they won’t achieve the cost and innovation benefits inher-
ent in these cross-industry partnerships. Further detail will be given on insights 
and challenges gleaned from interviewing large and small stakeholders as well as 
practical strategies, such as experimentation with data integration projects, to guide 
the transformation to a systems-thinking industry.
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objeCtives: To compare the relative efficacy and safety of golimumab, inflixi-
mab and adalimumab for the treatment of moderate-to-severe ulcerative colitis 
using indirect treatment comparison (ITC) meta-analysis. Methods: A system-
atic literature search identified five randomized controlled trials. Outcomes of 
interest included clinical remission, clinical response, mucosal healing, sustained 
remission/response, serious adverse events (SAEs), and discontinuation due to 
adverse events (DAEs). Data was synthesized using Bayesian indirect treatment 
comparison (ITC) meta-analysis. The analysis incorporated advanced intention-to-
treat with baseline priors to account for the alternative design of the golimumab 
trial. Results: After the induction phase, each treatment had significantly 
greater efficacy than placebo all endpoints, with the exception of adalimumab 
for mucosal healing. No statistical differences were observed between golimumab 
and infliximab. Adalimumab had significantly lower efficacy measures compared 
to infliximab for clinical remission (odds ratio [OR] 0.42, 95% credible interval 
[CrI] 0.17-0.97), clinical response (OR 0.45, 95% CrI 0.23-0.89), and mucosal healing 
(OR 0.46, 95% CrI 0.25-0.84) after the induction period. During the maintenance 
phase, each biologic agent exhibited significantly greater efficacy compared to 
placebo for clinical remission, clinical response, and mucosal healing. Golimumab 
100mg was significantly better than adalimumab for clinical response (OR 1.80, 
95% CrI 1.01-3.21) and mucosal healing at 54 weeks (OR 1.88, 95% CrI 1.01-3.49). No 
statistical differences were observed between adalimumab and infliximab. Both 
golimumab 100mg and infliximab were significantly better than adalimumab in 
terms of sustained clinical response (OR 2.40, 95% CrI 1.17-4.86 and OR 1.93, 95% CrI 
1.04-4.06), respectively. For SAEs, there were no statistical differences between any 
of the biologics and placebo. Although all biologics were generally safe, golimumab 
100mg had statistically significantly higher DAEs when compared to adalimumab 
(OR 2.09, 95% CrI 1.07-4.17). ConClusions: In the context of ITC meta-analysis, 
both golimumab and infliximab appear to demonstrate superior efficacy-safety 
profiles compared with adalimumab.
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objeCtives: Over 500,000 cholecystectomies are performed in the U.S. annually. 
The incidence of surgical site infection (SSI) is higher after open compared to 
laparoscopic cholecystectomy, but other procedural risk factors for SSI have not 
been well established. We investigated operative risk factors for SSI following 
cholecystectomy in a large cohort of privately insured patients. Methods: We 
performed a retrospective cohort study of persons aged 18–64 years with ICD-
9-CM procedure or CPT-4 codes for cholecystectomy from 1/1/2004–12/31/2010 
using commercial insurer claims data. Complex procedures and patients (e.g., 
cancer, end-stage renal disease) were excluded. SSIs occurring within 90 days 
after cholecystectomy were identified by ICD-9-CM diagnosis codes. Procedures 
in which SSI or septicemia was coded ≤ 30 days before surgery were also excluded. 
Multivariable logistic regression was used to determine independent risk factors 
for SSI, controlling for age. Results: A total of 113,138 cholecystectomy proce-
dures were identified; 76% were performed in females and the median age was 
43 years (range 18–64). A total of 833 (0.74%) SSIs occurred; the SSI incidence 
